Point-Of-Care Lateral Flow Reader Delivers High-Sensitivity Measurements In 10 Seconds
|
By LabMedica International staff writers Posted on 12 Aug 2024 |

A customizable point-of-care (POC) lateral flow reader combines advanced imaging technology and proprietary algorithms to deliver high-sensitivity measurements in just 10 seconds.
The miniDxR lateral flow reader designed by DCN Dx (Carlsbad, CA, USA) for POC testing offers advanced imaging technology, superior sensitivity and specificity, and robust cybersecurity features. It is customizable for diverse diagnostic applications, providing reliable and accurate results in diverse POC settings. The miniDxR utilizes advanced camera-based colorimetry and fluorescence for accurate and precise color and intensity detection, vital for the most sensitive POC diagnostics. It features a modular cartridge nest that can be customized to accommodate a wide variety of lateral flow assay cassettes, ensuring compatibility with a laboratory’s specific needs.
The miniDxR boasts a user-friendly interface with a vibrant color display and simple three-button control, enabling effortless operation even in fast-paced POC environments and while using gloves. Additional options are available to adapt screen size and button controls. It offers versatile “batch” and “single test” modes to accommodate diverse testing protocols, allowing labs to analyze pre-run assays or monitor lateral flow assays in real-time at the POC. Additionally, the miniDxR safeguards sensitive data with robust encryption and adheres to rigorous international standards, including FCC, IEC 61326, IEC 61010, IEC 60601, and IEC 62304, ensuring suitability for POC use.
The miniDxR offers a variety of customization options, from software workflows and data presentation to hardware modifications and branding. Every customized miniDxR unit comes with standard features such as pre-submission materials, product and software requirements, risk analysis, cybersecurity measures, verifications, and completion of the Design History File per FDA requirements. The miniDxR is designed to excel in both sophisticated clinical labs and challenging field environments.
"From its advanced capabilities to its range of customization options, our team designed this reader with the specific needs of point-of-care testing in mind," said Pat Vaughan, Ph.D., COO of DCN Dx.
Related Links:
DCN Dx
Latest Molecular Diagnostics News
- Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis
- AI Reveals Immune Response Biomarkers Linked to Ebola Survival
- Extracellular Vesicle Marker Identifies Early Lung Adenocarcinoma and Predicts Recurrence
- WHO Adds First Bundibugyo Ebola Molecular Test to Emergency Use Listing
- Blood Test Helps Guide Post-Surgical Treatment in Metastatic Colorectal Cancer
- Study Supports Earlier Genetic Testing for Hereditary Breast and Ovarian Cancer
- Noninvasive Biomarkers Advance Colorectal Cancer Risk Assessment
- Rapid Brush Biopsy Test Detects Oral Cancer in One Hour
- AI-Driven Blood Test Enhances Early Detection of Multiple Cancers
- Interpretable AI Tool Improves Prediction of Immunotherapy Response
- Blood Test Using Circular RNA Biomarkers Predicts Alzheimer’s Progression
- At-Home PCR Test Detects Flu and COVID-19 in 30 Minutes
- New Sequencing Platform Delivers Same-Day Whole-Genome Results
- Blood-Based RNA Biomarker Improves Prediction of Alzheimer’s Onset
- New Molecular Marker Helps Predict Multiple Myeloma Prognosis
- Gene Expression Test Supports Metastatic Risk Assessment in Melanoma
Channels
Clinical Chemistry
view channel
Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
Beckman Coulter Diagnostics has received CE Mark under IVDR for the Access p‑Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms... Read more
Alzheimer’s Biomarkers Identify Faster Cognitive Decline in Adults Over 80
Diagnosing the cause of cognitive decline in adults over 80 is challenging because multiple comorbidities can blur early clinical presentations. As a result, memory complaints are often attributed to normal... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
CE-Marked Blood Assay Automates Tuberculosis Infection Testing
Tuberculosis continues to pose a major global health challenge, with an estimated 10.7 million people falling ill and 1.23 million deaths in 2024. Roughly one quarter of the world’s population is believed... Read more
Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
Genomic surveillance is essential for detecting viral variants before they spread widely, yet many public health systems face high costs, uneven capacity, and computational barriers. Existing analytic... Read more
Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
Acute infectious gastroenteritis remains a major cause of illness worldwide, especially in young children, older adults, and immunocompromised patients. Nonspecific symptoms such as diarrhea, vomiting,... Read more
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read morePathology
view channel
New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
Recurrent breast cancer remains a persistent driver of morbidity and retreatment, and current risk stratification often depends on genomic assays that are costly and slow. Waiting weeks for results can... Read more
EBV Status Helps Predict Survival in Primary CNS Lymphoma
Primary central nervous system lymphoma is a rare malignancy in which tumors arise in the brain and, less often, the spinal cord, eyes, or cerebrospinal fluid. Outcomes are especially variable when the... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more




.jpg)



